Apitope has posted phase 2a data on the multiple sclerosis drug Merck KGaA walked away from last year.
VBL Therapeutics has presented more data from a phase 2 trial of VB-111 monotherapy in thyroid cancer patients.
From startups to leading global companies, Greater Fort Lauderdale provides a stimulating and supportive business environment for success in the life sciences.
Cidara Therapeutics will stop work on its antifungal CD101 in women with acute VVC, after the topical candidate failed a mid-stage trial.
Pfizer said the FDA has given its experimental leukemia med inotuzumab ozogamicin a priority review as it gets to work on assessing the medication for approval.
Sarepta has struck a $125 million deal to sell a voucher it got with last year’s controversial FDA approval of its new Duchenne drug to Gilead, which will give…
Nordic Nanovector CEO Luigi Costa has talked up the level of third-party interest in non-Hodgkin lymphoma candidate Betalutin.
The biotech's CEO says the clinical trial is the first to show that it is possible to usher large-molecule drugs across the blood-brain barrier.
After fluffing its lines in two mid-to-late stage trials in lung and colorectal cancer over the past few years, Daiichi and ArQule had hoped that tivantinib…
Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the…
Takeda and TiGenix have presented 52-week data on their stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas.